Breaking News Instant updates and real-time market news.

GKOS

Glaukos

$39.73

0.35 (0.89%)

08:18
08/03/17
08/03
08:18
08/03/17
08:18

Glaukos price target lowered to $54 from $60 at Roth Capital

Roth Capital analyst Chris Lewis lowered his price target for Glaukos to $54 from $60 on near-term transient headwinds. The analyst reiterates a Buy rating on the shares.

  • 15

    Aug

GKOS Glaukos
$39.73

0.35 (0.89%)

06/05/17
PIPR
06/05/17
NO CHANGE
Target $56
PIPR
Overweight
Glaukos drops after Piper Jaffray gets near-term cautious
Shares of Glaukos (GKOS) are lower after Piper Jaffray analyst Matt O'Brien said he's near-term cautious on the name after speaking to a high volume glaucoma specialist and cataract surgeon. Glaukos in late morning trading is down 5%, or $2.08, to $38.91. The doctor plans on switching some his iStent cases over to Alcon's CyPass once it is available, O'Brien told investors earlier in a research note. The introduction of CyPass, along with Noridian's Medicare reimbursement cut, has the analyst more near-term cautious on Glaukos shares. O'Brien, however, still sees a number of "key catalysts" for the name over the intermediate- to longer-term, including Inject and iDose. He kept an Overweight rating on Glaukos with a $56 price target.
05/22/17
STFL
05/22/17
NO CHANGE
STFL
Glaukos longer term outlook remains positive, says Stifel
After conducting checks with doctors, Stifel analyst Jonathan Block says Glaukos has "multi-billion dollar opportunities" that are not being reflected by its stock. The analyst says that the rate cut by Noridian has affected the profitability of iStent for doctors only minimally, while the the superior duration associated with Glaukos' iDose leaves it well-positioned to benefit from the multi-billion dollar sustained-release drug delivery market. The analyst keeps a $55 price target and a Buy rating on the stock.
05/12/17
ROTH
05/12/17
NO CHANGE
Target $60
ROTH
Buy
Glaukos recent weakness provides attractive entry point, says Roth Capital
After attending the American Society of Cataract and Refractive Surgery annual meeting, Roth Capital analyst Chris Lewis says MIGS adoption remains increasingly strong albeit still in relatively early stages, and Glaukos remains well-positioned as the clear MIGS market leader. The analyst believes the recent weakness on what he viewed as a "solid Q1" provides an attractive entry point on a more reasonable valuation. He reiterates a Buy rating and $60 price target on Glaukos' shares.
05/08/17
SPHN
05/08/17
UPGRADE
Target $49
SPHN
Overweight
Update: Glaukos upgraded to Overweight at Stephens
As previously reported before the open, Stephens analyst Chris Cooley upgraded Glaukos to Overweight from Equal Weight, saying that his recent checks increase his confidence in the adoption of Micro-Invasive Glaucoma Surgery. Additionally, data presented at the ASCRS meeting increase his optimism about the company's new products, added Cooley, who keeps a $49 price target on the stock.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.